Asia Pacific Clinical Trials Market 2021-2031

Bonafide Trust 03-04-2022 142 Pages
Region : Asia-Pacific Category : Lifescience Medical Devices

Request new version

Request for updated version of the report at the same price

Order Now

Highend Report

Highend report of this product is available

View

Report Description
Table of Contents
List of Figure Tables

Download Page

Asia Pacific clinical trials market will grow by 8.2% annually with a total addressable market cap of $104,282.0 million over 2022-2031, driven by the increasing number of clinical trials and increase in demand for novel therapies, rising prevalence on chronic diseases such as cancer and diabetes, the outbreak of tropical and infectious diseases such as COVID-19, and the increase in government initiatives and R&D investments. Highlighted with 36 tables and 78 figures, this 142-page report “Asia Pacific Clinical Trials Market 2021-2031 by Product Category (Drugs, Devices, Procedures), Phase (I, II, III, IV), Design (Interventional, Observational, Expanded Access), Service Type (Site Identification, Lab Services, Supply & Logistic, Decentralized Services), Indication (Oncology, Infectious Diseases, Cardiology, Obesity, Diabetes, Neurology), End User, and Country: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire Asia Pacific clinical trials market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2018-2021 and provides forecast from 2022 till 2031 with 2021 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.) In-depth qualitative analyses include identification and investigation of the following aspects: • Market Structure • Growth Drivers • Restraints and Challenges • Emerging Product Trends & Market Opportunities • Porter’s Fiver Forces The trend and outlook of Asia Pacific market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify Asia Pacific clinical trials market in every aspect of the classification from perspectives of Product Category, Phase, Design, Service Type, Indication, End User, and Country. Based on Product Category, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section. • Trials of Drugs o Small Molecule Drugs o Vaccines o Cell & Gene Therapy o Other Drugs • Trials of Devices • Trials of Procedures Based on Phase, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section. • Phase I • Phase II • Phase III • Phase IV By Design, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section. • Interventional Studies o Randomized Control Trial o Adaptive Clinical Trial o Non-randomized Control Trial • Observational Studies o Cohort Study o Case Control Study o Cross Sectional Study o Ecological Study • Expanded Access Trials By Service Type, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section. • Protocol Designing • Site Identification • Patient Recruitment • Laboratory Services • Bioanalytical Testing Services • Clinical Trial Data Management Services • Clinical Trial Supply & Logistic Services • Decentralized Clinical Trial Services • Medical Device Testing Services • Other Clinical Trial Services By Indication, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section. • Oncology • Infectious Diseases • Cardiology • Obesity • Diabetes • Neurology • Immunology • Pain Management • Other Indications By End User, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section. • Pharmaceutical and Biotechnological Companies • Clinical Research Organizations • Clinical Testing Laboratories • Other End Users Geographically, the following national/local markets are fully investigated: • Japan • China • South Korea • Australia • India • Rest of APAC (further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, Taiwan, and Philippines) For each key country, detailed analysis and data for annual revenue ($ mn) are available for 2021-2031. The breakdown of national markets by Phase, Design, and Indication over the forecast years are also included. The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players. Selected Key Players: Accell Clinical Research LLC Charles River Laboratory ClinDatrix Inc Clinipace Eli Lilly and Company F. Hoffmann-La Roche Ltd. ICON PLC IQVIA Holdings, Inc. Laboratory Corporation of America Novo Nordisk AS PAREXEL International Corporation Pfizer Inc. Pharmaceutical Product Development LLC PRA Health Sciences Sanofi SA SGS SA Syneos Health Inc. Wuxi AppTec Inc. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

1 Introduction 7

1.1 Industry Definition and Research Scope 7

1.1.1 Industry Definition 7

1.1.2 Research Scope 8

1.2 Research Methodology 11

1.2.1 Overview of Market Research Methodology 11

1.2.2 Market Assumption 12

1.2.3 Secondary Data 12

1.2.4 Primary Data 12

1.2.5 Data Filtration and Model Design 13

1.2.6 Market Size/Share Estimation 14

1.2.7 Research Limitations 15

1.3 Executive Summary 16

2 Market Overview and Dynamics 19

2.1 Market Size and Forecast 19

2.1.1 Impact of COVID-19 on World Economy 21

2.1.2 Impact of COVID-19 on the Market 23

2.2 Major Growth Drivers 25

2.3 Market Restraints and Challenges 32

2.4 Emerging Opportunities and Market Trends 35

2.5 Porter’s Fiver Forces Analysis 39

3 Segmentation of Asia Pacific Market by Product Category 43

3.1 Market Overview by Product Category 43

3.2 Trials of Drugs 45

3.2.1 Small Molecule Drugs 46

3.2.2 Vaccines 47

3.2.3 Cell & Gene Therapy 48

3.2.4 Other Drugs 49

3.3 Trials of Devices 50

3.4 Trials of Procedures 51

4 Segmentation of Asia Pacific Market by Phase 52

4.1 Market Overview by Phase 52

4.2 Phase I 54

4.3 Phase II 55

4.4 Phase III 56

4.5 Phase IV 57

5 Segmentation of Asia Pacific Market by Design 58

5.1 Market Overview by Design 58

5.2 Interventional Studies 60

5.2.1 Randomized Control Trial 62

5.2.2 Adaptive Clinical Trial 63

5.2.3 Non-randomized Control Trial 64

5.3 Observational Studies 65

5.3.1 Cohort Study 67

5.3.2 Case Control Study 68

5.3.3 Cross Sectional Study 69

5.3.4 Ecological Study 70

5.4 Expanded Access Trials 71

6 Segmentation of Asia Pacific Market by Service Type 72

6.1 Market Overview by Service Type 72

6.2 Protocol Designing 74

6.3 Site Identification 75

6.4 Patient Recruitment 76

6.5 Laboratory Services 77

6.6 Bioanalytical Testing Services 78

6.7 Clinical Trial Data Management Services 79

6.8 Clinical Trial Supply & Logistic Services 80

6.9 Decentralized Clinical Trial Services 81

6.10 Medical Device Testing Services 82

6.11 Other Clinical Trial Services 83

7 Segmentation of Asia Pacific Market by Indication 84

7.1 Market Overview by Indication 84

7.2 Oncology 86

7.3 Infectious Diseases 87

7.4 Cardiology 88

7.5 Obesity 89

7.6 Diabetes 90

7.7 Neurology 91

7.8 Immunology 92

7.9 Pain Management 93

7.10 Other Indications 94

8 Segmentation of Asia Pacific Market by End User 95

8.1 Market Overview by End User 95

8.2 Pharmaceutical and Biotechnological Companies 97

8.3 Clinical Research Organizations 98

8.4 Clinical Testing Laboratories 99

8.5 Other End Users 100

9 Asia-Pacific Market 2021-2031 by Country 101

9.1 Overview of Asia-Pacific Market 101

9.2 Japan 104

9.3 China 107

9.4 Australia 110

9.5 India 112

9.6 South Korea 114

9.7 Rest of APAC Region 116

10 Competitive Landscape 118

10.1 Overview of Key Vendors 118

10.2 New Product Launch, Partnership, Investment, and M&A 122

10.3 Company Profiles 123

Accell Clinical Research LLC 123

Charles River Laboratory 125

ClinDatrix Inc 126

Clinipace 127

Eli Lilly and Company 128

F. Hoffmann-La Roche Ltd. 129

ICON PLC 130

IQVIA Holdings, Inc. 131

Laboratory Corporation of America 132

Novo Nordisk AS 133

PAREXEL International Corporation 134

Pfizer Inc. 135

Pharmaceutical Product Development LLC 136

PRA Health Sciences 137

Sanofi SA 138

SGS SA 139

Syneos Health Inc. 140

Wuxi AppTec Inc. 141

RELATED REPORTS 142

List of Tables:

Table 1. Snapshot of Asia Pacific Clinical Trials Market in Balanced Perspective, 2021-2031 17
Table 2. Total Number of Registered Clinical Studies Worldwide, 2010-2021 20
Table 3. World Economic Outlook, 2021-2031 22
Table 4. World Health Spending by Region, $ bn, 2013-2020 31
Table 5. Main Product Trends and Market Opportunities in Asia Pacific Clinical Trials Market 35
Table 6. Asia Pacific Clinical Trials Market by Product Category, 2021-2031, $ mn 43
Table 7. Asia Pacific Clinical Trials Market: Trials of Drugs by Drug Type, 2021-2031, $ mn 45
Table 8. Asia Pacific Clinical Trials Market by Phase, 2021-2031, $ mn 52
Table 9. Asia Pacific Clinical Trials Market by Design, 2021-2031, $ mn 58
Table 10. Asia Pacific Clinical Trials Market: Interventional Studies by Segment, 2021-2031, $ mn 61
Table 11. Asia Pacific Clinical Trials Market: Observational Studies by Segment, 2021-2031, $ mn 66
Table 12. Asia Pacific Clinical Trials Market by Service Type, 2021-2031, $ mn 72
Table 13. Asia Pacific Clinical Trials Market by Indication, 2021-2031, $ mn 84
Table 14. Asia Pacific Clinical Trials Market by End User, 2021-2031, $ mn 95
Table 15. APAC Clinical Trials Market by Country, 2021-2031, $ mn 102
Table 16. Japan Clinical Trials Market by Phase, 2021-2031, $ mn 106
Table 17. Japan Clinical Trials Market by Design, 2021-2031, $ mn 106
Table 18. Japan Clinical Trials Market by Indication, 2021-2031, $ mn 106
Table 19. China Clinical Trials Market by Phase, 2021-2031, $ mn 108
Table 20. China Clinical Trials Market by Design, 2021-2031, $ mn 108
Table 21. China Clinical Trials Market by Indication, 2021-2031, $ mn 108
Table 22. Australia Clinical Trials Market by Phase, 2021-2031, $ mn 111
Table 23. Australia Clinical Trials Market by Design, 2021-2031, $ mn 111
Table 24. Australia Clinical Trials Market by Indication, 2021-2031, $ mn 111
Table 25. India Clinical Trials Market by Phase, 2021-2031, $ mn 113
Table 26. India Clinical Trials Market by Design, 2021-2031, $ mn 113
Table 27. India Clinical Trials Market by Indication, 2021-2031, $ mn 113
Table 28. South Korea Clinical Trials Market by Phase, 2021-2031, $ mn 115
Table 29. South Korea Clinical Trials Market by Design, 2021-2031, $ mn 115
Table 30. South Korea Clinical Trials Market by Indication, 2021-2031, $ mn 115
Table 31. Clinical Trials Market in Rest of APAC by Country/Region, 2021-2031, $ mn 117
Table 32. Percentage of Registered Studies by Location (as of February 24, 2022) 120
Table 33. Percentage of Recruiting Studies by Location (as of February 24, 2022) 120
Table 34. Accell Clinical Research LLC: Company Snapshot 123
Table 35. Accell Clinical Research LLC: Business Segmentation 124
Table 36. Accell Clinical Research LLC: Product Portfolio 124

List of Figures:

Figure 1. Research Method Flow Chart 11
Figure 2. Bottom-up Approach and Top-down Approach for Market Estimation 14
Figure 3. Asia Pacific Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2021-2031 16
Figure 4. Asia Pacific Clinical Trials Market, 2021-2031, $ mn 19
Figure 5. Impact of COVID-19 on Business 23
Figure 6. Primary Drivers and Impact Factors of Asia Pacific Clinical Trials Market 25
Figure 7. Percentage of Trial Participants by Country, 2015-2019 28
Figure 8. Leading Causes of Death in the World, 2019-2020, million 29
Figure 9. Worldwide Geriatric Population (60 years and above) by Regions, 2015 & 2030, million 30
Figure 10. World Population 65 and Over, % of Total Population, 1950-2060 30
Figure 11. Primary Restraints and Impact Factors of Asia Pacific Clinical Trials Market 32
Figure 12. Investment Opportunity Analysis 36
Figure 13. Porter’s Fiver Forces Analysis of Asia Pacific Clinical Trials Market 39
Figure 14. Breakdown of Asia Pacific Clinical Trials Market by Product Category, 2021-2031, % of Revenue 44
Figure 15. Asia Pacific Addressable Market Cap in 2022-2031 by Product Category, Value ($ mn) and Share (%) 44
Figure 16. Asia Pacific Clinical Trials Market by Product Category: Trials of Drugs, 2021-2031, $ mn 45
Figure 17. Asia Pacific Clinical Trials Market by Trials of Drugs: Small Molecule Drugs, 2021-2031, $ mn 46
Figure 18. Asia Pacific Clinical Trials Market by Trials of Drugs: Vaccines, 2021-2031, $ mn 47
Figure 19. Asia Pacific Clinical Trials Market by Trials of Drugs: Cell & Gene Therapy, 2021-2031, $ mn 48
Figure 20. Asia Pacific Clinical Trials Market by Trials of Drugs: Other Drugs, 2021-2031, $ mn 49
Figure 21. Asia Pacific Clinical Trials Market by Product Category: Trials of Devices, 2021-2031, $ mn 50
Figure 22. Asia Pacific Clinical Trials Market by Product Category: Trials of Procedures, 2021-2031, $ mn 51
Figure 23. Breakdown of Asia Pacific Clinical Trials Market by Phase, 2021-2031, % of Sales Revenue 53
Figure 24. Asia Pacific Addressable Market Cap in 2022-2031 by Phase, Value ($ mn) and Share (%) 53
Figure 25. Asia Pacific Clinical Trials Market by Phase: Phase I, 2021-2031, $ mn 54
Figure 26. Asia Pacific Clinical Trials Market by Phase: Phase II, 2021-2031, $ mn 55
Figure 27. Asia Pacific Clinical Trials Market by Phase: Phase III, 2021-2031, $ mn 56
Figure 28. Asia Pacific Clinical Trials Market by Phase: Phase IV, 2021-2031, $ mn 57
Figure 29. Breakdown of Asia Pacific Clinical Trials Market by Design, 2021-2031, % of Sales Revenue 59
Figure 30. Asia Pacific Addressable Market Cap in 2022-2031 by Design, Value ($ mn) and Share (%) 59
Figure 31. Asia Pacific Clinical Trials Market by Design: Interventional Studies, 2021-2031, $ mn 60
Figure 32. Asia Pacific Clinical Trials Market by Interventional Studies: Randomized Control Trial, 2021-2031, $ mn 62
Figure 33. Asia Pacific Clinical Trials Market by Interventional Studies: Adaptive Clinical Trial, 2021-2031, $ mn 63
Figure 34. Asia Pacific Clinical Trials Market by Interventional Studies: Non-randomized Control Trial, 2021-2031, $ mn 64
Figure 35. Asia Pacific Clinical Trials Market by Design: Observational Studies, 2021-2031, $ mn 65
Figure 36. Asia Pacific Clinical Trials Market by Observational Studies: Cohort Study, 2021-2031, $ mn 67
Figure 37. Asia Pacific Clinical Trials Market by Observational Studies: Case Control Study, 2021-2031, $ mn 68
Figure 38. Asia Pacific Clinical Trials Market by Observational Studies: Cross Sectional Study, 2021-2031, $ mn 69
Figure 39. Asia Pacific Clinical Trials Market by Observational Studies: Ecological Study, 2021-2031, $ mn 70
Figure 40. Asia Pacific Clinical Trials Market by Design: Expanded Access Trials, 2021-2031, $ mn 71
Figure 41. Breakdown of Asia Pacific Clinical Trials Market by Service Type, 2021-2031, % of Revenue 73
Figure 42. Asia Pacific Addressable Market Cap in 2022-2031 by Service Type, Value ($ mn) and Share (%) 73
Figure 43. Asia Pacific Clinical Trials Market by Service Type: Protocol Designing, 2021-2031, $ mn 74
Figure 44. Asia Pacific Clinical Trials Market by Service Type: Site Identification, 2021-2031, $ mn 75
Figure 45. Asia Pacific Clinical Trials Market by Service Type: Patient Recruitment, 2021-2031, $ mn 76
Figure 46. Asia Pacific Clinical Trials Market by Service Type: Laboratory Services, 2021-2031, $ mn 77
Figure 47. Asia Pacific Clinical Trials Market by Service Type: Bioanalytical Testing Services, 2021-2031, $ mn 78
Figure 48. Asia Pacific Clinical Trials Market by Service Type: Clinical Trial Data Management Services, 2021-2031, $ mn 79
Figure 49. Asia Pacific Clinical Trials Market by Service Type: Clinical Trial Supply & Logistic Services, 2021-2031, $ mn 80
Figure 50. Asia Pacific Clinical Trials Market by Service Type: Decentralized Clinical Trial Services, 2021-2031, $ mn 81
Figure 51. Asia Pacific Clinical Trials Market by Service Type: Medical Device Testing Services, 2021-2031, $ mn 82
Figure 52. Asia Pacific Clinical Trials Market by Service Type: Other Clinical Trial Services, 2021-2031, $ mn 83
Figure 53. Breakdown of Asia Pacific Clinical Trials Market by Indication, 2021-2031, % of Revenue 85
Figure 54. Asia Pacific Addressable Market Cap in 2022-2031 by Indication, Value ($ mn) and Share (%) 85
Figure 55. Asia Pacific Clinical Trials Market by Indication: Oncology, 2021-2031, $ mn 86
Figure 56. Asia Pacific Clinical Trials Market by Indication: Infectious Diseases, 2021-2031, $ mn 87
Figure 57. Asia Pacific Clinical Trials Market by Indication: Cardiology, 2021-2031, $ mn 88
Figure 58. Asia Pacific Clinical Trials Market by Indication: Obesity, 2021-2031, $ mn 89
Figure 59. Asia Pacific Clinical Trials Market by Indication: Diabetes, 2021-2031, $ mn 90
Figure 60. Asia Pacific Clinical Trials Market by Indication: Neurology, 2021-2031, $ mn 91
Figure 61. Asia Pacific Clinical Trials Market by Indication: Immunology, 2021-2031, $ mn 92
Figure 62. Asia Pacific Clinical Trials Market by Indication: Pain Management, 2021-2031, $ mn 93
Figure 63. Asia Pacific Clinical Trials Market by Indication: Other Indications, 2021-2031, $ mn 94
Figure 64. Breakdown of Asia Pacific Clinical Trials Market by End User, 2021-2031, % of Revenue 95
Figure 65. Asia Pacific Addressable Market Cap in 2022-2031 by End User, Value ($ mn) and Share (%) 96
Figure 66. Asia Pacific Clinical Trials Market by End User: Pharmaceutical and Biotechnological Companies, 2021-2031, $ mn 97
Figure 67. Asia Pacific Clinical Trials Market by End User: Clinical Research Organizations, 2021-2031, $ mn 98
Figure 68. Asia Pacific Clinical Trials Market by End User: Clinical Testing Laboratories, 2021-2031, $ mn 99
Figure 69. Asia Pacific Clinical Trials Market by End User: Other End Users, 2021-2031, $ mn 100
Figure 70. Breakdown of APAC Clinical Trials Market by Country, 2021 and 2031, % of Revenue 102
Figure 71. Contribution to APAC 2022-2031 Cumulative Market by Country, Value ($ mn) and Share (%) 103
Figure 72. Clinical Trials Market in Japan, 2021-2031, $ mn 105
Figure 73. Clinical Trials Market in China, 2021-2031, $ mn 107
Figure 74. Clinical Trials Market in Australia, 2021-2031, $ mn 110
Figure 75. Clinical Trials Market in India, 2021-2031, $ mn 112
Figure 76. Clinical Trials Market in South Korea, 2021-2031, $ mn 114
Figure 77. Clinical Trials Market in Rest of APAC, 2021-2031, $ mn 116
Figure 78. Growth Stage of Asia Pacific Clinical Trials Industry over the Forecast Period 118

Interested in this report?
Get your FREE sample!

Safe and Secure SSl Encryption

Licensing options

3200
USD

Single User License
Site License
Global User License

How client has rates us?

Requirement Gathering & Methodology

Data Collection Techniques

Our Research Team & Data Sourcing

Data Science & Analytical Tools

Data Visualization & Presentation Skills

Project/ Report Delivery & After Sales Services

Testimonial

READY TO MIX MARKET HAS HELPED US TO UNDERSTAND PRODUCT, PRICE & VARIENTS OF ALL THE COMPETITION INCLUDING SMALL STARTUPS/REGIONAL PLAYERS.

PRODUCT DEVELOPMENT MANAGER

CEO

Vivek Arora

BEING A STARTUP WE WERE NOT AWARE ABOUT E-COMMERCE LOGISTICS, THE REPORT HAS RESOLVED ALL OUR QUERIES. THE TEAM HAVE IN DEPTH KNOWLEDGE OF LOGISTICS. REMARKABLE!!

EXECUTIVE DIRECTOR

Rahul Roy

THE REPORT WAS GOOD FOR OUR STUDY, I WOULD STRONGLY RECOMMEND BONAFIDE RESEARCH. A VERY CUSTOMER CENTRIC AND APPROACHABLE TEAM.

SALES DIRECTOR

Arjun Prasad

THE COMPANY WHICH THOROUGHLY UNDERSTANDS INDIAN CONSUMER AND INDIAN MARKET. WE ARE REALLY HAPPY TO WORK WITH BONAFIDE RESEARCH

MARKETING MANAGER

President

Manish Verma

Bonafide Research did an outstanding work on Global Hand Sanitizer project. It was indeed a comprehensive report that gave us revenue impacting solution enabling us to plan the right move.

MARKETING DIRECTOR

Gautam Saxena

The study done by Bonafide Research was customized with all our needs. We were extremely impressed by the simple but comprehensive presentation of the study and the quality of work done.

PRODUCT MANAGER

Tom Stone

I’m glad I decided to work with you. Thankful to the team for the amazing coordination, it was indeed a good experience, would definitely recommend and come back for future prospects.

Associate Director

Mark Wood

Asia Pacific Clinical Trials Market 2021-2031

Asia Pacific Clinical Trials Market 2021-2031